Fine chemical

EQS-News: Successful 2024 Annual General Meeting of SCHOTT Pharma: Shareholders approve all items on the agenda

Retrieved on: 
Wednesday, April 10, 2024
Annual, EUR, Supervisory board, Frankfurt Stock Exchange, CFO, DAX, Election, Messenger, SDAX, Bank statement, Annual general meeting, SCHOTT, Fine chemical

EQS-News: SCHOTT Pharma AG & Co. KGaA

Key Points: 
  • EQS-News: SCHOTT Pharma AG & Co. KGaA
    Successful 2024 Annual General Meeting of SCHOTT Pharma: Shareholders approve all items on the agenda
    The issuer is solely responsible for the content of this announcement.
  • Successful 2024 Annual General Meeting of SCHOTT Pharma: Shareholders approve all items on the agenda
    SCHOTT Pharma's first Annual General Meeting was held virtually on March 14, 2024
    SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, held its first Annual General Meeting today.
  • The Annual General Meeting took place virtually and allowed shareholders to interact directly and ask questions to the Management Board and Supervisory Board.
  • “Holding our first Annual General Meeting marks the next milestone in our capital market history.

EQS-News: Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca

Retrieved on: 
Wednesday, April 10, 2024
PTHR1, AstraZeneca, Acromegaly, Patient, Sale, Acquisition, Endocrine disease, Cooley LLP, Centerview Partners, Alexion, Pharma, Hypoparathyroidism, Fine chemical

Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca

Key Points: 
  • Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca
    The issuer is solely responsible for the content of this announcement.
  • Alexion, AstraZeneca Rare Disease is looking forward to welcoming talent from Amolyt Pharma.
  • The company led by Thierry Abribat and an exceptional management team has developed innovative therapies for rare endocrine diseases.
  • Centerview Partners LLC and Goldman Sachs Bank Europe SE acted as financial advisors to Amolyt, and Cooley LLP and Jones Day acted as legal counsels for Amolyt and its shareholders.

Syngenta Group reports $32.2 billion sales and $4.6 billion EBITDA in 2023

Retrieved on: 
Wednesday, April 10, 2024
HTC, CER, Farmer, Pressure, Farm, Growth, Nutrition, Biologicals, Crop protection, Flower, Shanghai Stock Exchange, Syngenta, Acquisition, IPO, Seed, MAP, Soil, Huludao, Fine chemical

Full-year sales of Syngenta Crop Protection were 5 percent lower at $15.5 billion after exceptional growth in the previous year.

Key Points: 
  • Full-year sales of Syngenta Crop Protection were 5 percent lower at $15.5 billion after exceptional growth in the previous year.
  • ADAMA sales decreased 17 percent to $5.6 billion for the full year 2023, with significant channel destocking, particularly in the Americas, affecting the comparison.
  • Syngenta Seeds sales grew 2 percent to $4.8 billion in the full year 2023 in an overall growing seeds market.
  • Sales of Syngenta Group China, consisting of the Group’s Seeds, Crop Protection, Crop Nutrition, MAP and digital activities in China, grew 11 percent to $9.6 billion in the full year 2023.

DKSH Performance Materials Expands its Life Science Business in Malaysia by Acquiring Elite Organic Sdn. Bhd.

Retrieved on: 
Wednesday, April 10, 2024
BHD, Acquisition, DKSH, Food, CHF, Fine chemical

DKSH Performance Materials Expands its Life Science Business in Malaysia by Acquiring Elite Organic Sdn.

Key Points: 
  • DKSH Performance Materials Expands its Life Science Business in Malaysia by Acquiring Elite Organic Sdn.
  • DKSH has today announced to have signed an agreement to acquire Elite Organic Sdn.
  • This acquisition is a unique opportunity for DKSH to further expand our highly attractive life science business in Asia Pacific.
  • Thomas Sul and Natale Capri, Co-Heads Business Unit Performance Materials at DKSH, jointly added: “We are very pleased to acquire Elite Organic, which offers a strong product portfolio with excellent growth prospects in Malaysia.

Uni-Bio Science Group Announces 2023 Annual Results

Retrieved on: 
Wednesday, April 10, 2024
Escherichia coli, Gel, Prevalence, FN, Hip, Risk, Patient, Janet Woodcock, EGF, KL1, Yoy, Wound healing, Osteoporosis, CMO, Marketing, Dry eye syndrome, Government, Wrist, Genetic engineering, Ageing, Ophthalmology, Fine chemical

[27 March 2024 – Hong Kong] A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2023 (the “Year”).

Key Points: 
  • [27 March 2024 – Hong Kong] A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2023 (the “Year”).
  • The Group reached a significant milestone with the successful introduction of Skbrella™ FN, marking its entry into the advanced skincare raw material market.
  • In 2023, the Group recorded a revenue of approximately HK$484.7 million, representing an increase of 10.1 % YoY.
  • The Group strictly controlled its general and administrative expenses, which only accounted for 9.8% of revenue in 2023 as compared with 10.7% in 2022.

EQS-News: Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 to accelerate the development of its ADC Pipeline

Retrieved on: 
Wednesday, April 10, 2024
Translocase, Partner, 5T4, Growth, Science, Patient, Doctor of Philosophy, Spacecraft, Andera-ye Olya, AACR, ADC, Annual general meeting, Fine chemical

Tubulis is developing a pipeline of uniquely matched antibody drug conjugates (ADCs) with an indication-tailored targeting molecule and payload combination to develop novel ADCs with superior properties.

Key Points: 
  • Tubulis is developing a pipeline of uniquely matched antibody drug conjugates (ADCs) with an indication-tailored targeting molecule and payload combination to develop novel ADCs with superior properties.
  • The proceeds of the Series B2 will primarily support progress in Tubulis’ pipeline of next-generation ADCs toward clinical evaluation and help achieve clinical proof-of-concept for lead candidates, TUB-040 and TUB-030.
  • The company expects to start its first Phase 1/2a clinical trial, including dose escalation and dose optimization cohorts in 2024.
  • “This substantial financing from a syndicate of global specialist biotech investors recognizes Tubulis’ unique position in the ADC space.

EQS-News: KAP DEVELOPS IN LINE WITH ADJUSTED EXPECTATIONS IN A DIFFICULT ENVIRONMENT IN 2023 AND IMPLEMENTS FURTHER MEASURES TO INCREASE EFFICIENCY IN 2024 

Retrieved on: 
Wednesday, April 10, 2024
Annual, Annual report, Climate change, KAP, Tax, Normalization, Construction, Sale, Depreciation, Kingspan Group, Fine chemical

Normalised earnings before interest, taxes, depreciation and amortisation (normalised EBITDA) totalled €16.8 million in 2023, falling short of the previous year’s figure by 53.2%.

Key Points: 
  • Normalised earnings before interest, taxes, depreciation and amortisation (normalised EBITDA) totalled €16.8 million in 2023, falling short of the previous year’s figure by 53.2%.
  • This was due in particular to declines in earnings in the engineered products, flexible films and surface technologies segments.
  • Although we have developed in line with our adjusted expectations, we cannot be satisfied with our earnings for the year.
  • As part of the segment strategy, KAP continued to strategically develop its portfolio in the 2023 financial year.

EQS-News: Medios acquires Dutch market leader in pharmaceutical compounding services

Retrieved on: 
Wednesday, April 10, 2024
Tax, Consolidated, Growth, Frankfurt Stock Exchange, XETRA, FY, Patient, Pharmacy, Hospital, Acquisition, Laboratory, GMP, API, Depreciation, Fine chemical

Ceban is the Dutch market leader in compounding and has growing market positions in Belgium and Spain.

Key Points: 
  • Ceban is the Dutch market leader in compounding and has growing market positions in Belgium and Spain.
  • The purchase price for 100% of Ceban shares includes a cash component of €235.3 million and 1.7 million Medios shares.
  • The acquisition of Ceban gives Medios an outstanding position in the Dutch pharmaceutical market.
  • Ceban has a market leading position in pharmaceutical compounding in the Netherlands, a top-3 position in Belgium and a top-5 position in Spain.

HPS and Burcon to Showcase High Purity 95% Hempseed Protein Isolate at SupplySide East

Retrieved on: 
Wednesday, April 10, 2024
Drink, HPS, TSX, Taste, Traction, Fine chemical

Stop by the HPS Food & Ingredients booth #721 to learn more about this new-to-the-world, clean-label, high protein powder

Key Points: 
  • Burcon and HPS will present their best-in-class 95% hempseed protein isolate at SupplySide East, engaging with prospective customers interested in incorporating this clean-label protein into innovative food and beverage applications.
  • In response to significant demand, Burcon has successfully completed an additional production campaign for its hempseed protein to supply initial customer orders.
  • "Our new-to-the-world hempseed protein isolate continues to gain traction in the market, and we aim to sustain that momentum at SupplySide East," said Kip Underwood, Burcon's chief executive officer.
  • Attendees are invited to visit the HPS team at SupplySide East booth #721 for more information on the innovative hempseed protein isolate.

Burcon Successfully Scales Commercial Production of 95% Hempseed Protein Isolate

Retrieved on: 
Monday, March 25, 2024
HPS, TSX, Drink, Fine chemical

Burcon has achieved a significant milestone with the successful scale-up of its groundbreaking hempseed protein isolate at its partner manufacturer's production facility.

Key Points: 
  • Burcon has achieved a significant milestone with the successful scale-up of its groundbreaking hempseed protein isolate at its partner manufacturer's production facility.
  • From its production runs, Burcon produced high-quality, commercial saleable quantities of its 95% hempseed protein isolate to fulfill initial customer orders.
  • Anticipated commercial sales and further production campaigns of Burcon's hempseed protein are slated for the first half of 2024 to meet growing customer demand.
  • "We believe that the 95% hempseed protein isolate is a game changer that can tap into a burgeoning hemp foods market.